Fig. 1From: Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myelomaAnti-SARS-CoV-2 RBD antibody titers of 44 patients with multiple myeloma one month after two-dose SARS-CoV-2 mRNA vaccination. Results range from <0.4 to >250 U/mL with detectable antibody defined as an anti-SARS-CoV-2 RBD antibody titer >0.79 U/mL by the manufacturerBack to article page